- Takeda heeft zich kandidaat gesteld voor selectie op de “Prime Market” van de TSE
- Corporate Governance Rapport op basis van de herziene Corporate Governance Code ook ingediend bij TSE
- Gepubliceerde bijgewerkte documenten met betrekking tot corporate governance om de transparantie van corporate governance te helpen verbeteren
OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) heeft vandaag een aanvraag ingediend voor de selectie van het segment “Prime Market” van de Tokyo Stock Exchange, Inc. (“TSE” ) als zijn noteringsmarkt zoals bepaald tijdens de vergadering van de raad van bestuur op 29 en 30 september 2021. Takeda heeft de resultaten ontvangen van de eerste beoordeling door de TSE op 9 juli 2021, waarmee wordt bevestigd dat Takeda voldoet aan de noteringsvereisten voor de ” Prime Market” in de nieuwe marktsegmenten die op 4 april 2022 door de TSE worden geïntroduceerd. Bovendien heeft Takeda vandaag haar Corporate Governance-rapport ingediend bij de TSE op basis van de Corporate Governance Code, die op 11 juni 2021 is herzien. Dit rapport beschrijft de status van naleving van de openbaarmaking items die vereist zijn voor bedrijven die genoteerd zijn op de “Prime Market.”
Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website
- Takeda applied for selection to the “Prime Market” of the TSE
- Corporate Governance Report based on the revised Corporate Governance Code also filed with TSE
- Published updated corporate governance related documents to help enhance transparency of its corporate governance
OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today applied for selection of the “Prime Market” segment of the Tokyo Stock Exchange, Inc. (“TSE”) as its listing market as determined at the Board of Directors Meeting held on September 29 and 30, 2021. Takeda received the results of the initial assessment made by the TSE on July 9, 2021, confirming Takeda’s compliance with the listing requirements for the “Prime Market” in the new market segments that will be introduced on April 4, 2022 by the TSE. In addition, Takeda today filed its Corporate Governance Report with the TSE based on the Corporate Governance Code, which was revised on June 11, 2021. This report describes the status of compliance with the disclosure items required of companies listed on the “Prime Market.”
“As one of the largest R&D-driven biopharmaceutical companies in the world, and the only one listed on both the TSE and NYSE, our ambition is to build a world-class governance model to lead the company into the future” said Christophe Weber, Representative Director, President and CEO of Takeda.
Takeda also enhanced the Corporate Governance page of its website to improve the transparency of the company’s corporate governance and to promote understanding among its shareholders and investors. This includes publication of the company’s Articles of Incorporation, Board of Directors Charter, Nomination Committee Charter, Compensation Committee Charter, Audit and Supervisory Committee Charter, and Company Share Policy. The Corporate Governance Report and the corporate governance-related documents, can be found on the company’s corporate website at https://www.takeda.com/who-we-are/corporate-governance/.
“Being listed on the TSE’s ‘Prime Market’ will enable us to maximize our corporate value through increased transparency as well as further enhance our engagement with stakeholders including our shareholders and investors in Japan and around the world,” added Koki Sato, Corporate Strategy Officer and Chief of Staff of Takeda.
Takeda also furnished the English version of the Corporate Governance Report with the U.S. Securities and Exchange Commission (the “SEC”), available at www.sec.gov.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
+81 (0) 3-3278-2037
+81 (0) 3-3278-2306
Media Outside Japan